Oculis is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies. The Company’s leading clinical candidates include OCS-01 and OCS-02.
OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone using Oculis’ proprietary Solubilizing Nanoparticle (SNP) technology. It has successfully completed two Phase 2 clinical trials: in Diabetic Macular Edema and for treating inflammation and pain following cataract surgery.
OCS-02 is a novel topical anti-TNF alpha antibody and was in-licensed from Novartis. It has successfully completed two Phase 2 clinical trials in Acute Anterior Uveitis and in Dry Eye Disease.
